Teladoc Health, Inc. 8-K

What Happened
Teladoc Health, Inc. (TDOC) filed an 8-K reporting that, effective March 30, 2026, its Board increased to nine directors and appointed Susan R. Salka as a director. The Board also appointed her to the audit committee and the compensation committee and determined she is an independent director under NYSE rules and an "audit committee financial expert" under SEC/NYSE standards. The company issued a press release the same day.

Key Details

• Board size increased to nine directors as of March 30, 2026.
• Susan R. Salka appointed to the audit committee and the compensation committee.
• Board determined Ms. Salka is independent (per NYSE) and qualifies as an "audit committee financial expert" (per SEC/NYSE).
• No related-party arrangements or reportable transactions disclosed; Ms. Salka will have the same indemnification and non-employee director compensation eligibility as recent director appointees (see Proxy filed April 8, 2025).

Why It Matters
Adding an independent director who is designated as an audit committee financial expert strengthens the Board’s financial oversight and governance, which can matter to investors monitoring oversight of financial reporting and controls. The filing contains no financial results or executive departures—this is a governance update and does not by itself change company guidance or financials.